![]() |
市場調查報告書
商品編碼
1519991
全球蛋白質晶片市場 2024-2031Global Protein Chip Market 2024-2031 |
按類型(分析微陣列、功能蛋白微陣列和反相蛋白微陣列)、按應用(抗體表徵、臨床診斷和蛋白質組學)和最終用途(製藥和生物技術公司)分類的蛋白質晶片市場規模、佔有率和趨勢分析報告、學術和研究機構、診斷實驗室以及醫院和診所),預測期(2024-2031)
預計蛋白質晶片市場在預測期內(2024-2031)將以 6.4% 的複合年成長率成長。蛋白質晶片,也稱為蛋白質微陣列,是蛋白質體學中使用的一種高通量技術,用於在單一實驗中並行檢測和定量多種蛋白質。它由固體表面(通常是玻片或矽晶片)組成,其上以陣列形式固定有特定的捕獲分子(例如抗體、胜肽或蛋白質)。支持蛋白質微陣列市場成長的主要因素是對個人化醫療和精準診斷、技術投資和創新的需求不斷成長。
Protein Chip Market Size, Share & Trends Analysis Report by Type (Analytical Microarrays, Functional Protein Microarrays, and Reverse Phase Protein Microarrays), by Application (Antibody Characterization, Clinical Diagnostics, and Proteomics), and by End-Use (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Diagnostic Laboratories and Hospitals & Clinics), Forecast Period (2024-2031)
Protein chip market is anticipated to grow at a CAGR of 6.4% during the forecast period (2024-2031). A protein chip, also known as a protein microarray, is a high-throughput technology used in proteomics for the parallel detection and quantification of multiple proteins in a single experiment. It consists of a solid surface, typically a glass slide or a silicon chip, onto which specific capture molecules such as antibodies, peptides, or proteins are immobilized in an array format. Major factors supporting the protein microarray market growth are the increasing demand for personalized medicine and precision diagnostics, technological investments, and innovations.
Market Dynamics
Advancements in Protein Chip Technology: Revolutionizing Proteomics and Diagnostics
Technological advancements in protein chip technology have revolutionized the field of proteomics research and clinical diagnostics. These advancements encompass improvements in microarray fabrication, surface chemistry, and detection methods, leading to enhanced sensitivity, specificity, and multiplexing capabilities of protein chips. Advanced protein chip platforms enable the simultaneous analysis of thousands of proteins from complex biological samples, facilitating biomarker discovery, drug target identification, and pathway analysis with unprecedented speed and accuracy. These technological innovations drive the development of novel protein chip assays tailored for various research and clinical applications, fueling the growth of the global protein chip market. For instance, in December 2023, Theralink Technologies announced groundbreaking research conducted in collaboration with George Mason University and the University of California, San Francisco. Through the ISPY-2 trial, tumors from over 700 breast cancer patients were evaluated using Reverse Phase Protein Array (RPPA), uncovering novel therapeutic avenues for challenging breast cancers.
The Role of Protein Chips in Personalized Healthcare
Growing demand for personalized medicine is a significant driver shaping the trajectory of the global protein chip market. Personalized medicine aims to provide tailored therapeutic interventions based on individual patient characteristics, including genetic makeup, proteomic profile, and environmental factors. Protein chips play a crucial role in personalized medicine by enabling the identification of disease biomarkers, molecular signatures, and treatment responses at the molecular level. By analyzing protein expression patterns and signaling pathways in patient samples, protein chips empower clinicians to make informed decisions regarding patient care, treatment selection, and disease management strategies. As personalized medicine gains prominence in healthcare, the demand for protein chips as essential tools for molecular profiling and precision diagnostics continues to grow, driving market expansion and diversification of product offerings.
Market Segmentation
Functional Protein Microarrays is Projected to Emerge as the Largest Segment
The functional protein microarrays segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes its versatility and utility in high-throughput protein analysis. Functional protein microarrays enable the simultaneous screening of thousands of protein interactions, protein-protein binding events, enzyme activities, and post-translational modifications in a single experiment. This high-throughput capability accelerates the discovery of novel protein functions, biomarkers, drug targets, and therapeutic compounds, facilitating advancements in basic research, drug development, and clinical diagnostics.
Clinical Diagnostics Segment to Hold a Considerable Market Share
The clinical diagnostics segment holds a considerable market share due to its critical role in advancing personalized medicine and precision diagnostics. Protein chips are increasingly utilized in clinical settings for the rapid and accurate detection of various diseases, including cancer, cardiovascular disorders, infectious diseases, and neurological conditions. By analyzing protein expression patterns and identifying disease-specific biomarkers, protein chips enable clinicians to diagnose diseases at early stages, predict treatment responses, and monitor disease progression with high sensitivity and specificity. For instance, in November 2023, Octave Bioscience, Inc. secured a $10.0 million grant from The Michael J. Fox Foundation to develop a multi-analyte protein biomarker test for Parkinson's disease, aiming to improve disease assessment.
The global protein chip market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Empowering Precision Healthcare: Asia-Pacific's Rise in the Protein Chip Market
Asia-Pacific emerges as the fastest-growing market in the global protein chip sector due to several key drivers. The region's significant investments in healthcare infrastructure and research capabilities, propelled by economic expansion and government initiatives, foster the adoption of advanced technologies like protein chips. With a large and diverse population, including many affected by chronic and infectious diseases, Asia-Pacific offers a substantial market for protein-based diagnostic solutions, fueling demand for protein chips. Moreover, the region's increasing focus on precision medicine and personalized healthcare, coupled with collaborations between local and international players, further propels market growth. For instance, in February 2023, Sengenics introduced KREXTM technology to address challenges in efficiently producing fully functional proteins for clinical diagnostics, vaccine development, and drug discovery. Utilizing Biotin Carboxyl Carrier Protein (BCCP), this innovation enhances protein folding and solubility, enabling high-throughput expression of correctly folded proteins. Technology facilitates the simultaneous evaluation of numerous mutant proteins, offering insights into potential therapeutic interventions.
North America Holds Major Market Share
Among all the regions, North America holds a significant share due to its robust healthcare infrastructure, research ecosystem, and leading pharmaceutical companies drive substantial demand for protein chips in applications like drug discovery and personalized medicine. Additionally, the region's emphasis on healthcare innovation and technological advancement, coupled with favorable government initiatives and funding support, further propels the market growth. With a large patient population, particularly those with chronic diseases, North America presents significant opportunities for protein-based diagnostic solutions. For instance, in January 2024, Agilent Technologies unveiled the ProteoAnalyzer system, an innovative automated parallel capillary electrophoresis system designed for protein analysis. This platform enhances efficiency and simplifies the analysis of complex protein mixtures, benefiting various sectors including pharmaceuticals, biotechnology, and academic research.
The major companies serving the global protein chip market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Randox Laboratories Ltd., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in January 2022, Illumina collaborated with SomaLogic to integrate the SomaScan Proteomics Assay into Illumina's high-throughput next-generation sequencing (NGS) platforms. This partnership aims to cater to the rapidly expanding high-throughput proteomics market, facilitating significant scientific discoveries within the research community.